We are live on ! Find out more
NTC

North Tide Capital Portfolio holdings

AUM $469M
1-Year Est. Return 6.57%
This Fund
S&P 500
This Quarter Est. Return
+3.4%
1 Year Est. Return
+6.57%
3 Year Est. Return
+14.81%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.39B
AUM Growth
+$63.3M
Cap. Flow
+$76.7M
Cap. Flow %
5.54%
Top 10 Hldgs %
74.96%
Holding
28
New
8
Increased
3
Reduced
4
Closed
6

Top Buys

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$92.5M
2
GILD icon
Gilead Sciences
GILD
+$54.6M
3
SVU
SUPERVALU Inc.
SVU
+$52.4M
4
DGX icon
Quest Diagnostics
DGX
+$36.9M
5
STJ
St Jude Medical
STJ
+$36.1M

Top Sells

Rank Stock Value
1
BSX icon
Boston Scientific
BSX
+$79.9M
2
BHC icon
Bausch Health
BHC
+$49.7M
3
GHDX
Genomic Health, Inc.
GHDX
+$45.8M
4
ESRX
Express Scripts Holding Company
ESRX
+$43.4M
5
BAX icon
Baxter International
BAX
+$34.3M

Sector Composition

Rank Sector Weight
1 Healthcare 83.39%
2 Consumer Discretionary 3.6%
3 Technology 3.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GHDX
26
DELISTED
Genomic Health, Inc.
GHDX
– –
-1,500,000
Closed -$45.8M
FRED
27
DELISTED
Fred's Inc
FRED
– –
-638,900
Closed -$10.9M
ESRX
28
DELISTED
Express Scripts Holding Company
ESRX
– –
-500,000
Closed -$43.4M
1
2

Similar funds

SD
Sumway Development Shanghai, China $427M AUM 43.82% 1-Year Est. Return
DG
Davidson & Garrard Lynchburg, Virginia $425M AUM 14.62% 1-Year Est. Return
NBC
Neuberger Berman Canada Toronto, Ontario, Canada $542M AUM 14.17% 1-Year Est. Return
JWM
Jacobus Wealth Management Milwaukee, Wisconsin $382M AUM 16.31% 1-Year Est. Return
JPCCM
J&P (China) Capital Management Hong Kong, China $586M AUM 82.64% 1-Year Est. Return
MCL
MIK Capital LLC New York $344M AUM 26.72% 1-Year Est. Return
GIIO
Gen IV Investment Opportunities New York $269M AUM 21.06% 1-Year Est. Return
FC
FIC Capital New York $262M AUM 34.37% 1-Year Est. Return

North Tide Capital's Q2 2015 Portfolio in Review

As of Q2 2015, North Tide Capital held 28 positions worth $1.39B, up 4.8% from $1.32B the previous quarter. Its ten largest holdings account for 75% of the portfolio.

North Tide Capital deployed $76.7M of net new capital in Q2 2015, opening 8 new positions and adding to 3 existing holdings. Its largest new stake was Gilead Sciences: 500,000 shares worth $58.5M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, up from 83% a quarter earlier, followed by Consumer Discretionary and Technology.

On the sell side, the largest reduction was Community Health Systems, an estimated $27.1M trimmed.

  • North Tide Capital's largest Q2 2015 buy was Gilead Sciences: 500,000 shares worth $58.5M.
  • North Tide Capital added most to Teva Pharmaceuticals in Q2 2015, an estimated $92.5M increase.
  • North Tide Capital's biggest Q2 2015 reduction was Community Health Systems, cutting an estimated $27.1M.
  • North Tide Capital fully exited Boston Scientific in Q2 2015, selling an estimated $79.9M.
  • North Tide Capital's ten largest holdings make up 75% of its $1.39B portfolio in Q2 2015.
  • North Tide Capital opened 8 new positions and closed 6 in Q2 2015.
  • North Tide Capital's portfolio value rose 4.8% quarter-over-quarter to $1.39B.

Based on North Tide Capital's 13F filing for Q2 2015, filed 14 Aug 2015.